Edgar Filing: Basile Mark R - Form 4

Basile Mark Form 4	R								
May 01, 200								OMB AF	PPROVAL
Check th		ITIES AND EXCHANGE COMMISSION hington, D.C. 20549					3235-0287 January 31,		
if no lon subject to Section Form 4 c Form 5	ger o STATEN 16. or Filed pur	SEC	HANGES IN BENEFICIAL OWN SECURITIES				Expires: Estimated a burden hou response	2005 verage	
obligatio may con <i>See</i> Instr 1(b).	tinue. Section 17(blic Utility I the Investm	•	- ·		² 1935 or Section 0	n	
(Print or Type	Responses)								
1. Name and Address of Reporting Person <u>*</u> Basile Mark R			2. Issuer Name and Ticker or Trading Symbol BioMETRX [BMRX]				5. Relationship of Reporting Person(s) to Issuer		
(Last)	(First) (I		Date of Earlie				(Check	k all applicable	:)
、 <i>,</i>	DADWAY, SUIT	(N	Aonth/Day/Yea 4/26/2007				X Director X Officer (give below) Presi	X 10% title Othe below) dent and CEO	6 Owner er (specify
			If Amendmen led(Month/Day/	endment, Date Original nth/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person		
JERICHO,	NY 11743						Form filed by M Person		
(City)	(State)	(Zip)	Table I - No	on-Derivative	Securit	ies Acq	uired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution D any		4. Secur action(A) or D (Instr. 3, . 8)	isposed	of (D))	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial
Common			Code	V Amour	or		Transaction(s) (Instr. 3 and 4)		
Stock \$.001 par value	04/26/2007		J <u>(1)</u>	140,00	0 A	<u>(2)</u>	1,066,599	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Basile Mark R - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) Disposed of (Instr. 3, 4, a 5)) or (D)	6. Date Exercis Expiration Dat (Month/Day/Y	e	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Warrants	s \$1	04/26/2000		J <u>(1)</u>	140,000		04/26/2007	04/26/2012	Common Stock	140,00

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Basile Mark R 500 N. BROADWAY, SUITE 204 JERICHO, NY 11743	Х	Х	President and CEO				
Signatures							

gnata

/s/ Mark Basile	04/30/2007
<u>**</u> Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Biometrix, Inc. issued 140,000 shares of its Common Stock and 140,000 Common Stock Purchase Warrants exercisable at \$1.00 per

(1) share. The shares and warrants were issued to Mr. Basile as consideration for providing the copy with a loan in the principal amount of \$140,000

(2) N/A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.